natgillin/translations-raw huggingface dataset:
Imprida is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Imprida se ne preporučuje majkama koje doje, a ako želite dojiti liječnik Vam može odabrati drugo liječenje, posebno ako je Vaše dijete novorođenče ili je prijevremeno rođeno.
Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom 
Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR Velika Britanija
Amlodipine should be used with caution together with CYP3A4 inducers. 
Nužan je oprez prilikom primjene amlodipina zajedno s induktorima CYP3A4.
You must tell your doctor if you think you are (or might become) pregnant. 
Obratite se svom liječniku prije nego uzmete Impridu: ako ste bili bolesni (povraćanje ili proljev).
Imprida can be used with or without food. 
Imprida se može primjenjivati s hranom ili bez nje.
Do not take Imprida with grapefruit or grapefruit 
Ne uzimajte Impridu s grejpom ili sokom od grejpa.
The safety of Imprida has been evaluated in five controlled clinical studies with 5,175 patients, 2,613 of whom received valsartan in combination with amlodipine. 
Sigurnost Impride je ispitivana u pet kontroliranih kliničkih ispitivanja s 5175 bolesnika, od kojih je 2613 primalo valsartan u kombinaciji s amlodipinom.
Do not use any Imprida pack that is damaged or shows signs of tampering. 
Ne koristiti Impridu ako primijetite da je pakovanje oštećeno ili su vidljivi znakovi otvaranja.
All packs are available with standard blisters; the 56, 98 and 280 tablet packs are additionally available with perforated unit dose blisters. 
Sva pakovanja su dostupna sa standardnim blisterima; pakovanja s 56, 98 i 280 tableta su dodatno dostupna s perforiranim blisterima djeljivim na jedinične doze.
Multipack: 280 (4 packs of 70) film-coated tablets Multipack: 280 (20 packs of 14) film-coated tablets 
Višestruko pakovanje: 280 (4 pakovanja od 70) filmom obloženih tableta Višestruko pakovanje: 280 (20 pakovanja od 14) filmom obloženih tableta
Stopping your treatment with Imprida may cause your disease to get worse. 
Prestanak liječenja Impridom može dovesti do pogoršanja bolesti od koje bolujete.
No information is available regarding the use of Imprida during breast-feeding, therefore Imprida is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant. 
Budući da nisu dostupne informacije o primjeni Impride tijekom dojenja, stoga se Imprida tijekom dojenja ne preporučuje te se savjetuje alternativno liječenje s bolje utvrđenim sigurnosnim profilom tijekom dojenja, posebno kod dojenja novorođenčeta ili nedonoščeta.
Imprida has not been studied in any patient population other than hypertension. 
Imprida nije ispitivana ni u jednoj drugoj populaciji bolesnika, osim u bolesnika s hipertenzijom.
For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be switched to Imprida containing the same component doses. 
Bolesnici koji primaju valsartan i amlodipin u odvojenim tabletama/kapsulama, mogu se radi jednostavnosti prebaciti na Impridu koja sadrži iste doze sastojaka.
The rate and extent of absorption of Imprida are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets. 
Brzina i opseg apsorpcije Impride jednaki su bioraspoloživosti valsartana i amlodipina kada se primjenjuju kao pojedinačne tablete.
Clinically significant hypotension due to Imprida overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. 
Klinički značajna hipotenzija zbog predoziranja Impridom zahtijeva aktivnu kardiovaskularnu potporu, uključujući često praćenje srčane i respiratorne funkcije, podizanje ekstremiteta, uz praćenje volumena cirkulirajuće tekućine i mokrenja.
If you forget to take Imprida 
Ako ste zaboravili uzeti Impridu
Imprida combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. 
Imprida kombinira dva antihipertenzivna sastojka s komplementarnim mehanizmima kontrole krvnog tlaka u bolesnika s esencijalnom hipertenzijom: amlodipin pripada skupini kalcijevih antagonista, dok valsartan pripada skupini antagonista angiotenzina II.
Pack sizes: 56, 98 or 280 film-coated tablets. 
Veličina pakovanja: 56, 98 ili 280 filmom obloženih tableta.
Imprida is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets. 
Imprida je dostupna u pakovanjima koja sadrže 7, 14, 28, 30, 56, 90, 98 ili 280 tableta i u višestrukim pakovanjima koji sadrže 4 kutije, od kojih svaka sadrži 70 tableta, ili 20 kutija, od kojih svaka sadrži 14 tableta.
CARTON OF UNIT PACK 
KUTIJA JEDINIČNOG PAKOVANJA
If hypotension occurs with Imprida, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. 
Ako se uz Impridu pojavi hipotenzija, bolesnika treba poleći na leđa i po potrebi, mu dati intravensku infuziju fiziološke otopine.
Posology The recommended dose of Imprida is one tablet per day. 
Doziranje Preporučena doza Impride je jedna tableta na dan.
• Concomitant use of Imprida with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
• Istodobna primjena Impride s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR <60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
Imprida should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients. 
Imprida se treba primjenjivati s oprezom u liječenju hipertenzije u bolesnika s jednostranom ili obostranom stenozom bubrežne arterije ili stenozom bubrežne arterije kod postojanja samo jednog bubrega budući da se u ovih bolesnika može povisiti urea u krvi i serumski kreatinin.
Interactions common to the combination No drug-drug interaction studies have been performed with Imprida and other medicinal products. 
Interakcije koje su česte kod ove kombinacije Nisu provedena ispitivanja interakcija među lijekovima s Impridom i drugim lijekovima.
Additional information on the individual components Adverse reactions previously reported with one of the individual components (amlodipine or valsartan) may be potential adverse reactions with Imprida as well, even if not observed in clinical trials or during the post-marketing period. 
Dodatne informacije o pojedinačnim komponentama Nuspojave koje su ranije prijavljene s jednom od pojedinačnih komponenti (amlodipinom ili valsartanom) mogu biti i moguće nuspojave Impridu, iako nisu uočene u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet.
Imprida tablets contain two substances called amlodipine and valsartan. 
Imprida tablete sadrže dvije djelatne tvari koje se zovu amlodipin i valsartan.
* Mostly consistent with cholestasis 
* uglavnom upućuje na kolestazu
* mostly consistent with cholestasis 
* Uglavnom upućuje na kolestazu
The amlodipine component of Imprida inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. 
Amlodipinska komponenta Impride inhibira transmembranski ulaz iona kalcija u srčani mišić i glatki mišić krvnih žila.
Abrupt withdrawal of Imprida has not been associated with a rapid increase in blood pressure. 
Nagli prekid primjene Impride nije bio povezan s naglim povišenjem krvnog tlaka.
If any of the above applies to you, do not take Imprida and talk to your doctor. 
Ako se bilo što od navedenog odnosi na Vas, nemojte uzeti Impridu i obavijestite svog liječnika.
The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. 
Istodobna primjena induktora CYP3A4 (npr. rifampicin, Hypericum perforatum) mogla bi imati za posljedicu nižu koncentraciju amlodipina u plazmi.
If any of these apply to you, tell your doctor before taking Imprida. 
Ako se bilo što od navedenog odnosi na Vas, obavijestite svog liječnika prije uzimanja Impride.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). 
Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, ARB-ova ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
Following oral administration of Imprida, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6-8 hours, respectively. 
Nakon peroralne primjene Impride, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6-8 sati.
Pack sizes: 7, 14, 28, 30, 56, 90, 98 or 280 film-coated tablets and multipacks containing 280 (4x70 or 20x14) film-coated tablets. 
Veličina pakovanja: 7, 14, 28, 30, 56, 90, 98 ili 280 filmom obloženih tableta i višestruko pakovanje koje sadrži 280 (4x70 ili 20x14) filmom obloženih tableta.
Side effects reported with amlodipine or valsartan alone and either not observed with Imprida or observed with a higher frequency than with Imprida: 
Prijavljene nuspojave s amlodipinom ili valsartanom primjenjenima samostalno ili uopće nisu opažene s Impridom ili su opažene s većom učestalošću nego s Impridom:
Imprida was also studied in an active-controlled study of 130 hypertensive patients with mean sitting diastolic blood pressure ≥110 mmHg and <120 mmHg. 
Imprida je također ispitivana u aktivno kontroliranom kliničkom ispitivanju sa 130 hipertenzivnih bolesnika sa srednjom vrijednošću dijastoličkog krvnog tlaka u sjedećem položaju ≥110 mmHg i <120 mmHg.
ACE inhibitors or aliskiren (see also information under the headings “Do not take Imprida” and diuretics (a type of medicine also called “water tablets” which increases the amount of urine lithium (a medicine used to treat some types of depression); potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; certain types of painkillers called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2 inhibitors). 
ACE inhibitori ili aliskiren (vidjeti također informacije pod naslovom „Nemojte uzimati Impridu“ i „Upozorenja i mjere opreza“); diuretici (vrsta lijeka koja se naziva i „tablete za mokrenje“ koje povećavaju količinu mokraće koju proizvodite); litij (lijek koji se koristi za liječenje nekih vrsta depresije); diuretici koji štede kalij, nadomjesci kalija, zamjene za sol koje sadrže kalij i ostale tvari koje mogu povećati razinu kalija; određene vrste lijekova protiv bolova koji se nazivaju nesteoridni protuupalni lijekovi (NSAILi) ili selektivnim inhibitorima ciklooksigenaze-2 (COX-2 inhibitori).
Imprida should be discontinued immediately in patients who develop angioedema and should not be re-administered. 
Bolesnici u kojih se razvije angioedem trebaju odmah prekinuti primjenu Impride i više ga ne smiju ponovo uzimati.
Frequency Imprida Amlodipine Valsartan 
Učestalost Imprida Amlodipin Valsartan
In this study (baseline blood pressure 171/113 mmHg), an Imprida regimen of 5 mg/160 mg titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg. 
U tom ispitivanju (početni krvni tlak 171/113 mmHg), liječenje Impridom 5 mg/160 mg titriranim do 10 mg/160 mg snizilo je krvni tlak u sjedećem položaju za 36/29 mmHg, u usporedbi s 32/28 mmHg kod liječenja lizinoprilom/hidroklorotiazidom 10 mg/12,5 mg titriranim do 20 mg/12,5 mg.
In one rat study, adverse effects were found on male fertility (see section 5.3). 
U jednom ispitivanju sa štakorima nađeni su štetni učinci na mušku plodnost (vidjeti dio
Imprida is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own. 
Imprida se primjenjuje za liječenje povišenog krvnog tlaka u odraslih osoba čiji krvni tlak nije dovoljno kontroliran bilo samo amlodipinom ili samo valsartanom.
Imprida is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. 
Imprida je indicirana u odraslih osoba čiji krvni tlak nije odgovarajuće kontroliran monoterapijom amlodipinom ili valsartanom.
Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with Imprida in placebo-controlled studies. 
U placebo-kontroliranim ispitivanjima, u 0,4% bolesnika s nekompliciranom hipertenzijom liječenih Impridom viđena je izražena hipotenzija.
Others 
Drugi
medicines used to treat fungal infections (e.g. ketoconazole, itraconazole); medicines used to treat bacterial infections (such as rifampicin, erythromycin, clarithromycin, talithromycin); verapamil, diltiazem (heart medicines); simvastatin (a medicine used to control high cholesterol levels); dantrolene (infusion for severe body temperature abnormalities); medicines used to protect against transplant rejection (ciclosporin). 
lijekovi koji se primjenjuju za liječenje HIV infekcije/SIDA (npr. ritonavir, indinavir, nelfinavir); lijekovi za liječenje gljivičnih infekcija (npr. ketokonazol, itrakonazol); lijekovi za liječenje bakterijskih infekcija (npr. rifampicin, eritromicin, klaritromicin, talitromicin); verapamil, diltiazem (lijekovi za srce); simvastatin (lijekovi koji se koriste za kontrolu visokih razina kolesterola); dantrolen (infuzija za teške poremećaje tjelesne temperature); lijekovi koji se koriste kao zaštita od odbacivanja transplantata (ciklosporin).
The active substances of Imprida are amlodipine (as amlodipine besylate) and valsartan. 
Djelatne tvari u Impridi su amlodipin (u obliku amlodipinbesilata) i valsartan.
Very rare Very rare Very rare 
Manje često Često Rijetko Manje često -Vrlo rijetko
Hepatic impairment Imprida is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Imprida je kontraindicirana u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
• Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the 
• Preosjetljivost na djelatne tvari, derivate dihidropiridina, ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Fertility There are no clinical studies on fertility with Imprida. 
Ne postoje klinička ispitivanja djelovanja Impride na plodnost.
Pitting oedema 
Quinckeov edem
Caution should be exercised when administering Imprida to patients with hepatic impairment or biliary obstructive disorders (see section 4.4). 
Nužan je oprez kod primjene Impride bolesnicima s oštećenjem jetre ili opstruktivnim bolestima žučnog sustava (vidjeti dio 4.4).
Particular caution should be exercised when administering Imprida to patients with mild to moderate hepatic impairment or biliary obstructive disorders. 
Nužan je poseban oprez kod primjene Impride bolesnicima s blagim do umjerenim oštećenjem jetre ili opstruktivnim poremećajima žučnog sustava.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida. 
Grejp i sok od grejpa u nekih bolesnika može dovesti do povećanja razina djelatne tvari amlodipina u krvi, što može uzrokovati neočekivano pojačani učinak na snižavanje krvnog tlaka.
Amlodipine stops calcium from moving into the blood vessel wall which stops the blood vessels from 
Amlodipin sprečava ulazak kalcija u stijenku krvne žile i tako sprečava sužavanje krvne žile.
Cellulose microcrystalline Crospovidone Type A Silica, colloidal anhydrous Magnesium stearate 
A silicijev dioksid, koloidni, bezvodni magnezijev stearat
Imprida 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Imprida 5 mg/160 mg. 
Imprida 10 mg/160 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 10 mg ili valsartanom 160 mg ili s Impridom 5 mg/160 mg.
Imprida 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone. 
Imprida 5 mg/80 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 80 mg.
No dosage adjustment of Imprida is required for patients with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2). 
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m2) doziranje Impride nije potrebno prilagođavati.
Not known Very rare Not known 
Nepoznato Vrlo rijetko Nepoznato
- Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson Syndrome) or other allergic reactions. 
- Teške kožne reakcije, uključujući intenzivan kožni osip, koprivnjaču, crvenilo kože po čitavom tijelu, jaki svrbež, stvaranje mjehurića, ljuštenje i oticanje kože, upalu sluznica (Stevens
Imprida 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone. 
Imprida 5 mg/160 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 160 mg.
There are no available clinical data in severely renally impaired patients. 
Klinički podaci u bolesnika s teškim oštećenjem bubrega nisu dostupnia.
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum) There is no data available regarding the effect of CYP3A4 inducers on amlodipine. 
CYP3A4 induktori (antikonvulzivni lijekovi [npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon], rifampicin, Hypericum perforatum)
Your doctor may also check your kidney function; anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone); St. John's wort; nitroglycerin and other nitrates, or other substances called “vasodilators”; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir); 
Liječnik će Vam možda provjeriti i bubrežnu funkciju; antikonvulzivni lijekovi (npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon); gospina trava; nitroglicerin i drugi nitrati, ili drugi lijekovi koji se nazivaju „vazodilatatori“;
Hypromellose Titanium dioxide (E171) Iron oxide, yellow (E172) Macrogol 4000 
Ovojnica: hipromeloza titanijev dioksid (E171) željezov oksid, žuti (E172) makrogol 4000 talk
Hypromellose Titanium dioxide (E171) Iron oxide, yellow (E172) Iron oxide, red (E172) Macrogol 4000 
Ovojnica: hipromeloza titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172) makrogol 4000 talk
Imprida 5 mg/80 mg film-coated tablets 
Imprida 5 mg/80 mg filmom obložene tablete
Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida. 
Bolesnici koji uzimaju Impridu ne smiju konzumirati grejp ili sok od grejpa.
When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or Imprida, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. 
Prilikom prebacivanja starijih hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) na amlodipin ili Impridu, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
The other ingredients are cellulose microcrystalline; crospovidone type A; silica, colloidal anhydrous; magnesium stearate; hypromellose; macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172), iron oxide, red (E172). 
Drugi sastojci su mikrokristalična celuloza, krospovidon tipa A, koloidni bezvodni silicijev dioksid, magnezijev stearat, hipromeloza, makrogol 4000, talk, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172).
Imprida 10 mg/160 mg film-coated tablets 
Imprida 10 mg/160 mg filmom obložene tablete
The other ingredients are cellulose microcrystalline; crospovidone type A; silica, colloidal anhydrous; magnesium stearate; hypromellose; macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172). 
Drugi sastojci su mikrokristalična celuloza, krospovidon tipa A, koloidni bezvodni silicijev dioksid, magnezijev stearat, hipromeloza, makrogol 4000, talk, titanijev dioksid (E171), žuti željezov oksid (E172).
Imprida 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Imprida 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Imprida, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. 
Prilikom prebacivanja hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) s oštećenjem jetre na amlodipin ili Impridu, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET
Imprida 5 mg/80 mg film-coated tablets amlodipine/valsartan 
Imprida 5 mg/80 mg filmom obložene tablete amlodipin/valsartan
What Imprida looks like and contents of the pack Imprida 10 mg/160 mg tablets are oval and light yellow with “NVR” on one side and “UIC” on the other side. 
Imprida 10 mg/160 mg tablete su ovalne, svijetložute tablete, s oznakom „NVR“ na jednoj strani i „UIC“ na drugoj strani.
Imprida 5 mg/160 mg film-coated tablets 
Imprida 5 mg/160 mg filmom obložene tablete
EU/1/06/373/035 280 film-coated tablets (4x70) EU/1/06/373/038 280 film-coated tablets (20x14) 
EU/1/06/373/035 280 filmom obloženih tableta (4x70) EU/1/06/373/038 280 filmom obloženih tableta (20x14)
EU/1/06/373/036 280 film-coated tablets (4x70) EU/1/06/373/039 280 film-coated tablets (20x14) 
EU/1/06/373/036 280 filmom obloženih tableta (4x70) EU/1/06/373/039 280 filmom obloženih tableta (20x14)
EU/1/06/373/034 280 film-coated tablets (4x70) EU/1/06/373/037 280 film-coated tablets (20x14) 
EU/1/06/373/034 280 filmom obloženih tableta (4x70) EU/1/06/373/037 280 filmom obloženih tableta (20x14)
Imprida 5 mg/160 mg film-coated tablets amlodipine/valsartan 
Imprida 5 mg/160 mg filmom obložene tablete amlodipin/valsartan
What Imprida looks like and contents of the pack Imprida 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side. 
Imprida 5 mg/80 mg tablete su okrugle, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „NV“ na drugoj strani.
Facial oedema 
Posturalna omaglica
If you think you may be allergic, talk to your doctor before taking Imprida. 
Ako mislite da biste mogli biti alergični, porazgovarajte sa svojim liječnikom prije uzimanja Impride. ako imate teške probleme s jetrom ili probleme sa žuči, poput bilijarne ciroze ili kolestaze.
What Imprida looks like and contents of the pack Imprida 5 mg/160 mg tablets are oval and dark yellow “NVR” on one side and “ECE” on the other side. 
Imprida 5 mg/160 mg tablete su ovalne, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „ECE“ na drugoj strani.